ACLX

Arcellx Inc

Add to Watchlist

Advanced Chart

64.710

+0.160(+0.250%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

65.630

Open

64.200

VWAP

64.57

Vol

359.59K

Mkt Cap

3.56B

Low

62.760

Amount

23.22M

EV/EBITDA(TTM)

Total Shares

53.50M

2.97B

EV/OCF(TTM)

P/S(TTM)

32.03

Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

19.87M

-23.65%

-0.768

+60.05%

19.47M

-28.89%

-0.767

+50.48%

19.51M

-50.3%

-0.739

+427.62%

Estimates Revision

The market is revising Downward the revenue expectations for Arcellx, Inc. (ACLX) for FY2025, with the revenue forecasts being adjusted by -25.05% over the past three months. During the same period, the stock price has changed by -4.25%.

Revenue Estimates for FY2025

Revise Downward

-25.05%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+33.55%

In Past 3 Month

Stock Price

Go Down

-4.25%

In Past 3 Month

15 Analyst Rating

81.04% Upside

Wall Street analysts forecast ACLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACLX is 117.15 USD with a low forecast of 104.00 USD and a high forecast of 134.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

15 Buy

0 Hold

0 Sell

Strong Buy

81.04% Upside

Current: 64.710

Low

104.00

Averages

117.15

High

134.00

81.04% Upside

Current: 64.710

Low

104.00

Averages

117.15

High

134.00

Needham

Gil Blum

Strong Buy

Reiterates

$105

2024-12-10

Reason

Needham

Gil Blum

Price Target

$105

2024-12-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Emily Bodnar

Strong Buy

Reiterates

$115

2024-12-10

Reason

HC Wainwright & Co.

Emily Bodnar

Price Target

$115

2024-12-10

Reiterates

Strong Buy

Reason

UBS

Ashwani Verma

Strong Buy

Maintains

$106 → $114

2024-12-10

Reason

UBS

Ashwani Verma

Price Target

$106 → $114

2024-12-10

Maintains

Strong Buy

Reason

UBS analyst Ashwani Verma raised the firm's price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes Arcellx's anito-cel has generated similar efficacy and better safety profile compared to Legend Biotech's (LEGN) Carvykti, and while Legend bulls may argue Arcellx "cherry-picked" patients, the firm believes that the data speaks for itself and settles the debate, the analyst tells investors in a research note.

Needham

Gil Blum

Strong Buy

Reiterates

$105

2024-12-09

Reason

Needham

Gil Blum

Price Target

$105

2024-12-09

Reiterates

Strong Buy

Reason

Truist Securities

Asthika Goonewardene

Strong Buy

Maintains

$87 → $136

2024-11-12

Reason

Truist Securities

Asthika Goonewardene

Price Target

$87 → $136

2024-11-12

Maintains

Strong Buy

Reason

Needham

Gil Blum

Strong Buy

Maintains

$96 → $105

2024-11-08

Reason

Needham

Gil Blum

Price Target

$96 → $105

2024-11-08

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Arcellx Inc (ACLX.O) is -21.36, compared to its 5-year average forward P/E of -21.56. For a more detailed relative valuation and DCF analysis to assess Arcellx Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-21.56

Current PE

-21.36

Overvalued PE

-6.92

Undervalued PE

-36.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-18.30

Current EV/EBITDA

-15.85

Overvalued EV/EBITDA

-6.83

Undervalued EV/EBITDA

-29.76

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

38.20

Current PS

39.34

Overvalued PS

92.58

Undervalued PS

-16.19

Financials

Annual

Quarterly

FY2024Q4

YoY :

-75.83%

15.27M

Total Revenue

FY2024Q4

YoY :

-454.37%

-53.15M

Operating Profit

FY2024Q4

YoY :

-337.26%

-47.08M

Net Income after Tax

FY2024Q4

YoY :

-312.20%

-0.87

EPS - Diluted

FY2024Q4

YoY :

-189.75%

-47.53M

Free Cash Flow

FY2024Q4

YoY :

0.00%

100.00

Gross Profit Margin - %

FY2024Q4

YoY :

-153.21%

-89.78

FCF Margin - %

FY2024Q4

YoY :

-1081.54%

-308.40

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

290.0K

USD

3-6

Months

19.4M

USD

6-9

Months

5.6M

USD

0-12

Months

6.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 102.12% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.2M

Volume

6-9

Months

0.0

Volume

0-12

Months

602.2K

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.0M

Volume

Months

6-9

0.0

Volume

Months

0-12

4.5M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

290.0K

USD

3-6

Months

19.4M

USD

6-9

Months

5.6M

USD

0-12

Months

6.1M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

ACLX News & Events

Events Timeline

2025-02-27 (ET)

2025-02-27

16:04:17

Arcellx reports FY24 EPS ($2.00), consensus ($1.50)

2025-01-03 (ET)

2025-01-03

06:06:43

Opco lists five potential biotech targets into JPMorgan conference

2024-12-09 (ET)

2024-12-09

04:41:52

Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole

News

9.5

04-02Benzinga

Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

9.0

03-18Newsfilter

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

6.0

03-14Business Insider

Barclays Sticks to Its Buy Rating for Arcellx Inc (ACLX)

People Also Watch

GAIN

Gladstone Investment Corp

Lincoln Educational Services Corp

Alerus Financial Corp

Montana Technologies Corp

Northfield Bancorp Inc

Evolv Technologies Holdings Inc

Senseonics Holdings Inc

Flushing Financial Corp

12.450

USD

+0.81%

FAQ

What is Arcellx Inc (ACLX) stock price today?

The current price of ACLX is 64.71 USD — it has increased 0.25 % in the last trading day.

ACLX

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

ACLX News & Events

Events Timeline

News

People Also Watch

FAQ

What is Arcellx Inc (ACLX) stock price today?

What is Arcellx Inc (ACLX)'s business?

What is the price predicton of ACLX Stock?

What is Arcellx Inc (ACLX)'s revenue for the last quarter?

What is Arcellx Inc (ACLX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Arcellx Inc (ACLX)'s fundamentals?

How many employees does Arcellx Inc (ACLX). have?

What is Arcellx Inc (ACLX) market cap?